Nature Aging finds aging-related diseases uniquely reward further progress

Most economic arguments for fighting aging start from biology: find the master switch, slow the clock, and every downstream disease eases at once. The Nature Aging Analysis published on 2 September makes the case on different ground. It groups diseases not by mechanism but by when in life they hit hardest, and finds that one of those groups behaves unlike the others when you push against it.

The paper, "Reframing the epidemiological transition as increasing returns to tackling aging-related diseases" by Julian Ashwin, David Bloom, Naomi Lee, Peter Piot and Andrew Scott, runs a K-means clustering on Global Burden of Disease data and sorts causes into four life-cycle clusters: infant, early-adult, later-adult and aging-related. According to the paper, the aging-related cluster (ischemic heart disease and other cardiovascular conditions, COPD, chronic kidney disease, type 2 diabetes, some cancers, Parkinson's, dementia) shows increasing returns, while the other three are close to linear. Cut aging-related prevalence and each further cut is worth more than the last. That property, the authors argue, is what should reorder how health systems think about the century ahead.

The finding: one cluster where progress compounds

The number that carries the argument is a ratio. In the paper's DALY model, per the PDF, a 50 percent reduction in aging-related disease prevalence is worth around 2.2 times a 25 percent reduction by 2050, and a 100 percent reduction around 5.9 times. By 2100 those ratios rise to 3.2 and 10.7. Non-aging-related clusters, the authors write, stay close to linear: each proportional cut against infant or early-adult disease buys roughly what the last one did, or slightly less.

That is the whole of the claim, and it is worth being precise about what it is and is not. It is a statement about welfare gains as modelled through disability-adjusted life years, under illustrative reduction scenarios the paper itself calls non-realistic. The 25, 50 and 100 percent cuts are not forecasts. They are a way of asking how the value of progress scales, and the answer for aging-related disease is that it scales up.

The mechanism the paper offers is a correlation. Across age brackets, it reports the link between mortality and disability at 0.50 for aging-related diseases, against 0.04 for infant, -0.009 for early-adult and -0.03 for later-adult. Where death and disability move together, a gain against one is amplified by a simultaneous gain in the other, and within a cluster of diseases that compete for the same lives, removing one raises the return on removing the next. Multiply those effects and returns rise rather than flatten. The authors state that eradicating aging-related diseases outright would raise remaining global life expectancy at age 70 by 125 percent, with the largest gains in upper-middle-income countries at 135 percent and the smallest in low-income countries at 103 percent.

Why this is not the biology bet in new clothes

The temptation is to read this as the "target aging" thesis restated. It is not, and the authors are careful about the gap. Their labels are statistical: a disease is aging-related here because its burden rises with age, not because a shared malleable aging process has been shown to drive it. The Discussion says so directly, and flags that further life-expectancy gains could reclassify some diseases out of the cluster entirely, that cross-cluster linkages such as infection accelerating chronic disease are ignored by construction, and that the increasing-returns result rests on DALYs and disability weights that may miss economic or quality-of-life effects of longer lives.

This matters for how much weight the finding can bear. Andrew Scott, the corresponding author, made a stronger and more biological version of the case in a 2021 Nature Aging paper with Ellison and Sinclair, which put the value of a one-year slowdown in aging at US$38 trillion and closed on the line that the more progress is made in improving how we age, the greater the value of further improvements. The 2026 paper is not the first time this author group has argued that gains compound. What is new is the route: it reaches a similar conclusion from a life-cycle clustering of GBD burden, without assuming a single aging process exists. That makes the claim more robust to being wrong about the biology, and correspondingly more modest about what it proves. It tells you where the returns are, not why.

The reframing that does the work

The epidemiological transition is usually told as a one-way street: as life expectancy rises, deaths shift from infection to chronic disease, and that shift is treated as something that happens to a society rather than something it chooses. The paper's contribution is to argue that once life expectancy clears roughly 70 years, the shape of the remaining burden creates a decision rather than a destination. Aging-related diseases are, per the authors, already the largest part of current global disease burden and the greatest lifetime burden for a newborn in every income group. Even in low-income countries, where infant disease still looms large, the lifetime totals nearly meet: 9.05 DALYs for aging-related against 9.03 for infant.

That near-equality in the poorest countries is the detail that keeps the paper honest. It would be easy to read the whole argument as a rich-world concern, a problem for societies that have already beaten the diseases of the young. The 9.05-versus-9.03 figure says the crossover is closer to universal than that, which is what lets the authors claim the choice they describe is a global one. The choice, on their framing, is between spreading survival to more people and concentrating gains on aging better, and the increasing-returns property is a thumb on the scale for the second.

Where the argument is exposed

The strongest objection is not to the clustering but to the currency. The entire increasing-returns result is denominated in DALYs, and DALYs are a construction: they weight a year of disability against a year of life by fixed disability weights, and they say nothing about what a longer life costs to sustain or what it produces. The authors concede this. If the economic consequences of longer lives run the other way, through pension systems, care burdens or the compression of productive years, the value proposition the paper models could shrink. A finding that says progress compounds under one welfare metric is a finding about that metric until the accounting is done in another.

There is a second exposure the paper builds in itself. Its clusters are defined by today's age-burden shapes, and it says plainly that pushing life expectancy higher could move diseases between clusters. The increasing-returns property is therefore a statement about the world as it is measured now, not a fixed law. Should a wave of progress against aging-related disease itself reshape which diseases count as aging-related, the ratios would have to be recomputed on the new distribution. The paper is a snapshot of where the leverage sits, offered as a reason to act, not a guarantee that acting leaves the leverage where it found it.

What would falsify the core claim is specific: recompute the same GBD clustering with a welfare measure that captures the economic and quality-of-life effects DALYs omit, and if the aging-related cluster no longer shows returns rising faster than prevalence cuts, the reframing collapses into the ordinary observation that chronic disease is where the burden now lives. Until someone runs that, the paper has done something narrower and more useful than the headline suggests. It has shown that under the metric public health already uses to allocate effort, one cluster of diseases rewards further progress at an increasing rate, and it has named that cluster. The next move belongs to whoever sets research and funding priorities against GBD numbers, because the paper has just told them the marginal dollar against aging-related disease is worth more than the last one, and that the same is not true anywhere else on the chart.